Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of KL0011034 in Healthy Chinese Volunteers
NCT07474545Phase 1Recruiting
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KL0011034 (3 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoint: Number of reported Adverse Events at Day 2. Started Mar 2026; status: recruiting.
02
Drugs
KL0011034
Beyond the preview
Go deeper on NCT07474545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474545.